The role of mitochondria in MDS

Myelodysplastic Syndromes: Pathobiology and Clinical Management, Second Edition

Volumn , Issue , 2008, Pages 127-151

  Gattermann, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651294653     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (132)

1. Jacobs A, Bowen DT. Pathogenesis and evolution of refractory anaemia. In: Mufti GJ, Galton DAG, eds. The Myelodysplastic Syndromes. Edinburgh: Churchill Livingstone, 1992:33-53.
2. Juneja SK, Imbert M, Sigaux S, et al. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol 1983; 36:566-569.
3. Maldonado JE, Maigne J, Lecoq D. Comparative electron-microscopic study of the erythrocytic line in refractory anemia (preleukemia) and myelomonocytic leukemia. Blood Cells 1976; 2:167-185.
4. Sakura T, Murakami H, Saitoh T, et al. Ultrastructural abnormalities of bone marrow erythroblasts in refractory anemia. Ultrastruct Pathol 1998; 22:173-180.
5. Cohen AM, Alexandrova S, Bessler H, et al. Ultrastructural observations on bone marrowcells of 26 patients with myelodysplastic syndromes. Leuk Lymphoma 1997; 27:165-172.
6. van de Loosdrecht AA, Brada SJL, Blom NR, et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. Leuk Res 2001; 25:385-393.
7. Rötig A, Cormier V, Koll F, et al. Site-specific deletions of the mitochondrial genome in the Pearson marrow-pancreas syndrome. Genomics 1991; 10:502-504.
8. Houwerzijl E, Pol H-W, Blom N, et al. Erythroid precursors from patients with lowrisk myelodysplasia demonstrate ultrastructural features of autophagy. Blood 2007; 110(11, abstract #2444).
9. AokiY. Multiple enzymatic defects in mitochondria in hematological cells of patients with primary sideroblastic anemia. J Clin Invest 1980; 66:43-49.
10. Matthes TW, Meyer G, Samii K, et al. Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol 2000; 111:843-852.
11. Matthes T, Rustin P, Trachsel H, et al. Different pathophysiological mechanisms of intramitochondrial iron accumulation in acquired and congenital sideroblastic anemia caused by mitochondrial DNA deletion. Eur J Haematol 2006; 77:169-174.
12. Bowen D, Peddie C. Mitochondrial oxygen consumption and ineffective haematopoiesis in patients with myelodysplastic syndromes. Br J Haematol 2002; 18:345-346.
13. Thompson JE, Conlon JP, Yang X, et al. Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol 2007; 35:21-31.
14. Fracchiolla NS, Catena FB, Novembrino C, et al. Possible association between reactive oxygen metabolites and karyotypic abnormalities in myelodysplastic syndromes. Haematologia (Budap) 2003; 88:594-596.
15. Ghoti H, Amer J, Winder A, et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndromes. Eur J Haematol 2007; 79:463-467.
16. PeddieC, Wolf CR, McLellan LI, et al. OxidativeDNAdamage inCD34+myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor concentration. Br J Haematol 1997; 99:625-631.
17. Bowen D, Wang L, FrewM, et al. Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: Further evidence of a pathogenetic role for oxidative stress? Haematologica 2003; 88:1070-1072.
18. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003; 77:342-350.
19. Craven SE, French D, Weilan Y, et al. Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndromes. Blood 2005; 105:3528-3534.
20. Chen TH, Walshauser M, Kambal A, et al. Reduced HSPA9B expression, a 5q31.2 candidate gene, in primary human CD34+ cells recapitulates features of ineffective hematopoiesis observed in MDS. Blood 2007 (ASH 2007, abstract #4564).
21. SankaranVG, Walkley CR, Spiegelman BM, et al. Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis. Blood 2007(ASH 2007, abstract #638).
22. Freeman KB, Haldar D. The inhibition of mammalian mitochondrial NADH oxidation by chloramphenicol and its isomers and analogues. Can J Biochem 1968; 46:1003-1008.
23. Bottomley SS. Sideroblastic anemias. In: Lee GR, Foerster J, Lukens JN, Paraskevas F, Greer JP, Rodgers G, eds.Wintrobe’s Clinical Hematology. 10th ed. Philadelphia, Baltimore: Lippincott Williams and Wilkins, 1998:1022-1045.
24. Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002; 100:1493-1495.
25. Williams DM, Loukopoulos D, Lee GR, et al. Role of copper in mitochondrial iron metabolism. Blood 1976; 48:77-85.
26. Goodman JR, Dallman PR. Role of copper in iron localization in developing erythrocytes. Blood 1969; 34:747-753.
27. Harman D. Ageing:Atheory based on free radical and radiation chemistry. J Gerontol 1956; 11:298-300.
28. Harman D. Ageing: Overview. Ann N Y Acad Sci 2001; 928:1-21.
29. Feng J, Bussiere F, Hekimi S. Mitochondrial electron transport is a key determinant of life span in Caenorhabditis elegans. Developmental Cell 2001; 1:633-644.
30. Lindsay DG. Diet and ageing: The possible relation to reactive oxygen species. J Nutr Health Aging 1999; 3:84-91.
31. de Grey AD. The reductive hotspot hypothesis of mammalian ageing: Membrane metabolism magnifies mutant mitochondrial mischief. Eur J Biochem 2002; 269:2003-2009.
32. de Grey AD. Three detailed hypotheses implicating oxidative damage to mitochondria as a major driving force in homeotherm aging. Eur J Biochem 2002; 269:1995.
33. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283:1482-1488.
34. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, ageing, and cancer: A dawn for evolutionary medicine. Annu Rev Genet 2005; 39:359-407.
35. Cortopassi GA, Shibata DD, SoongNW, et al.Apattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc Natl Acad Sci USA 1992; 89:7370-7374.
36. Corral-Debrinski M, Shoffner JM, Lott MT, et al. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res 1992; 275:169-180.
37. Kadenbach B, Munscher C, FrankV, et al. Human ageing is associated with stochastic somatic mutations of mitochondrial DNA. Mutat Res 1995; 338:161-172.
38. Brierley EJ, Johnson MA, Lightowlers RN, et al. Role of mitochondrial DNA mutations in human aging: Implications for the central nervous system and muscle. Ann Neurol 1998; 43:217-223.
39. Murdock DG, Christiacos NC, Wallace DC. The age-related accumulation of a mitochondrial DNA control region mutation in muscle, but not brain, detected by a sensitive PNA-directed PCR clamping based method. Nucleic Acids Res 2000; 28:4350-4355.
40. Coller HA, Bodyak ND, Khrapko K. Frequent intracellular clonal expansions of somatic mtDNA mutations. Ann NY Acad Sci 2002; 959:434-447.
41. Richter C. Reactive oxygen and DNA damage in mitochondria. Mutat Res 1992; 275:249-255.
42. Yakes FM, van Houten B. MitochondrialDNAdamage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94:514-519.
43. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988; 85:645-646.
44. Marcelino LA, Thilly WG. Mitochondrial mutagenesis in human cells and tissues. Mutat Res 1999; 434:177-203.
45. Khrapko K, Coller HA, Andre PC, et al. Mitochondrial mutational spectra in human cells and tissues. Proc Natl Acad Sci USA 1997; 94:13798-13803.
46. Wang E, Wong A, Cortopassi G. The rate of mitochondrial mutagenesis is faster in mice than in humans. Mutat Res 1997; 377:157-166.
47. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005; 6:389-402.
48. Shin MG, Kajigaya S, McCoy JP, et al. Marked mitochondrial DNA sequence heterogeneity in single CD34+ cell clones from normal adult bone marrow. Blood 2004; 103:553-561.
49. OgasawaraY, Nakayama K, Tarnowka M, et al. MitochondrialDNAspectra of single human CD34+ cells, T cells, B cells, and granulocytes. Blood 2005; 106:3271-3284.
50. Yao Y-G, Ellison FM, McCoy JP, et al. Age-dependent accumulationof mtDNA mutations in murine hematopoietic stem cells is modulated by the nuclear genetic background. Hum Mol Genet 2007; 16:286-294.
51. Krishnan KJ, Greaves LC, Reeve AK, et al. The ageing mitochondrial genome. Nucleic Acids Res 2007; 35:7399-7405.
52. Khrapko K, Kraytsberg Y, de Grey AD, et al. Does premature aging of the mtDNA mutator mouse prove that mtDNA mutations are involved in natural aging? Aging Cell 2006; 5:279-282.
53. Vermulst M, Bielas JH, Kujoth G, et al. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 2007; 39:540-543.
54. Khrapko K, Vijg J. Mitochondrial DNA mutations and aging: A case closed? Nat Genet 2007; 39:445-446.
55. Gattermann N, Berneburg M, Heinisch J, et al. Detection of the ageing-associated 5-Kb deletion of mitochondrial DNA in blood and bone marrow of hematologically normal adults. Absence of the deletion in clonal bone marrow disorders. Leukemia 1995; 9:1704-1710.
56. Morrison SJ, Wandycz AM, Akashi K, et al. The aging of hematopoietic stem cells. Nat Med 1996; 2:1011-1016.
57. Marley SB, Lewis JL, Davidson RJ, et al. Evidence for a continuous decline in haematopoietic cell function from birth: Application to evaluating bone marrow failure in children. Br J Haematol 1999; 106:162-166.
58. Geiger H, van Zant G. The aging of lympho-hematopoietic stem cells. Nature Immunology 2002; 3:329-333.
59. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429:417-423.
60. Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309:481-484.
61. Chen M, Kundu M, Shelat S, et al. Animal model of mitochondrial dysfunction generating macrocytic anemia and myelodysplastic bone marrow failure. Blood 2007(ASH 2007, abstract #5382).
62. Trifunovic A, Hansson A, Wredenberg A, et al. Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci USA 2005; 102:17993-17998.
63. Inoue S, Yokota S, Nakada K, et al. Pathogenic mitochondrial DNA-induced respiration defects in hematopoietic cells result in anemia by suppressing erythroid differentiation. FEBS Lett 2007; 581:1910-1916.
64. Gattermann N, Retzlaff S, Wang YL, et al. A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non-lymphoid cell lineages from a patient with acquired idiopathic sideroblastic anaemia. Br J Haematol 1996; 93:845-855.
65. Gattermann N, Retzlaff S, Wang Y-L, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90:4961-4972.
66. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 2000; 24:141-151.
67. Gattermann N, Wulfert M, Junge B, et al. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242 A) in a patient with myelodysplastic syndrome. Blood 2004; 103:1499-1502.
68. Bröker S, Meunier B, Rich P, et al. MtDNA mutations associated with sideroblastic anaemia cause a defect of mitochondrial cytochrome c oxidase. Eur J Biochem 1998; 258:132-138.
69. Wulfert M, Küpper AC, Tapprich C, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 2008; 36:577-586.
70. Wulfert M, Tapprich C, Gattermann N. Optimized mtDNA fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC. J Chromatogr B Biomed Appl 2006; 831:236.
71. Shin MG, Kajigaya S, Levin BC, et al. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 2003; 101:3118-3125.
72. He L, Luo L, Proctor SJ, et al. Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia 2003; 17:2487-2491.
73. Linnartz B, Anglmayer R, Zanssen S. Comprehensive scanning of somatic mitochondrial DNA alterations in acute leukemia developing from myelodysplastic syndromes. Cancer Res 2004; 64:1966-1971.
74. Grist SA, Lu X-J, Morley AA. Mitochondrial mutations in acute leukemia. Leukemia 2004; 18:1313-1316.
75. Yao Y-G, Ogasawara Y, Kajigaya S, et al. Mitochondrial DNA sequence variation in single cells from leukemia patients. Blood 2007; 109:756-762.
76. Carew JS, Zhou Y, Albitar M, et al. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: Clinical significance and therapeutic implications. Leukemia 2003; 17:1437-1447.
77. Penta JS, Johnson FM, Wachsman JT, et al. Mitochondrial DNA in human malignancy. Mutat Res 2001; 488:119-133.
78. Salas A, Yao Y-G, Macaulay V, et al. A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Medicine 2005; 2:1158-1166 (e296).
79. Porra RJ, Jones OTG. Studies on ferrochelatase. Biochem J 1963; 87:181-192.
80. Grasso JA, Myers TJ, Hines JD, et al. Energy-dispersive X-ray analysis of the mitochondria of sideroblastic anaemia. Br J Haematol 1980; 46:57-72.
81. Shirihai OS, Gregory T, Yu C, et al. ABC-me: A novel mitochondrial transporter induced by GATA-1 during erythroid differentiation. The EMBO J 2000; 19:2492-2502.
82. Flachs P, Sponarova J, Kopecky P, et al. Mitochondrial uncoupling protein 2 gene transcript levels are elevated in maturing erythroid cells. FEBS Lett 2007; 581:1093-1097.
83. Lange H, Kispal G, Lill R. Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria. J Biol Chem 1999; 274:18989-18996.
84. Mühlenhoff U, Stadler JA, Richhardt N, et al. A specific role of the yeast mitochondrial carriers MRS3/4p in mitochondrial iron acquisition under iron-limiting conditions. J Biol Chem 2003; 278:40612-40620.
85. Shaw GC, Cope JJ, Li L, et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006; 440:96-100.
86. Kushner JP, Lee GR, Wintrobe MM, et al. Idiopathic refractory sideroblastic anemia. Clinical and laboratory investigation of 17 patients and review of the literature. Medicine (Baltimore) 1971; 50:139-159.
87. Pasanen AVO, Vuopio P, Borgström GH, et al. Heme biosynthesis in refractory sideroblastic anaemia associated with the preleukaemic syndrome. Scand J Haematol 1981; 27:35-44.
88. Steensma DP, Hecksel KA, Porcher JC, et al. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). Leuk Res 2007; 31:623-628.
89. Cazzola M, Invernizzi R, Bergamaschi G, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101:1996-2000.
90. Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106:247-253.
91. della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006; 20:549-555.
92. Santambrogio P, Biasiotto G, Sanvito F, et al. Mitochondrial ferritin expression in adult mouse tissues. J Histochem Cytochem 2007; 55:1129-1137.
93. Nie G, Sheftel AD, Kim SF, et al. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 2005; 105:2161-2167.
94. Muta K, Krantz SB. Inhibition of heme synthesis induces apoptosis in human erythroid progenitor cells. J Cell Physiol 1995; 163:38-50.
95. Nakajima O, Takahashi S, Harigaee H, et al. Heme deficiency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload. EMBO J 1999; 18:6282-6289.
96. Fuhler GM, Hooijenga F, Drayer AL, et al. Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. Exp Hematol 2003; 31:752-759.
97. Houwerzijl E, Blom N, Van DerWant JJ, et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 2005; 105:3472-3479.
98. Houwerzijl E, Blom N, van der Want JJ, et al. Megakaryocyte dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006:1937-1942.
99. Braun T, Carvalho G, Grosjean J, et al. Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation. Apoptosis 2007; 12:1101-1108.
100. Ott M, Gogvadze V, Orrenius S, et al. Mitochondria, oxidative stress and cell death. Apoptosis 2007; 12:913-922.
101. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268-276.
102. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11:839-845.
103. Hellström-Lindberg E, Schmidt-Mende J, Forsblom AM, et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112:714-726.
104. Shetty V, Hussaini S, Alvi S, et al. Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic patients. Br J Haematol 2002; 116:817-825.
105. Tehranchi T, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101:1080-1086.
106. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004; 18:1176-1199.
107. Claessens YE, Park S, Dubart-Kupperschmitt A, et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 2005; 105:4035-4042.
108. Fontenay M, Cathelin S, Amiot M, et al. Mitochondria in hematopoiesis and hematological diseases. Oncogene 2006; 25:4757-4767.
109. Tehranchi R, Fadeel B, Schmidt-Mende J, et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: Concordance between in vitro and in vivo observations. Clin Cancer Res 2005; 11:6291-6299.
110. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6:513-519.
111. Wolvetang EJ, Johnson KL, Krauer K, et al. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett 1994; 339:40-44.
112. Wang J, Silva JP, Gustafsson CM, et al. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci USA 2001; 98:4038-4043.
113. Schildgen V, Junge B, Gattermann N. Impaired mitochondrial gene expression in MDS patients. Leuk Res 2007; 31(Suppl. 1):S35.
114. Parker JE, Fishlock KL, Mijovic J, et al. ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus antiapoptotic bcl-2-related proteins. Br J Haematol 1998; 103:1075-1082.
115. Berger G, Hunault-Berger M, Rachieru P, et al. Increased apoptosis in mononucleated cells but not CD34+ cells in blastic forms of myelodysplastic syndromes. Haematol J 2001; 2:87-96.
116. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990; 74:45-52.
117. Germing U, Gattermann N, Aivado M, et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): A time-tested distinction. Br J Haematol 2000; 108:724-728.
118. van Duppen V, Raets V, Raeymaekers L, et al. CD34+ progenitors from low-risk MDS patients are more susceptible to induced oxidative damage and have reduced DNA repair compared to healthy control subjects. Blood 2003; 102(11), abstract #3410.
119. Jankowska AM, Gondek LP, Szpurka H, et al. Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia 2008; 22:551-558.
120. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 1995; 312:163-167.
121. Wickramasinghe SN, Hughes M. Capacity of ringed sideroblasts to synthesize nucleic acids and protein in patients with primary acquired sideroblastic anaemia. Br J Haematol 1978; 38:345-352.
122. Löffler M, ockel J, Schuster G, et al. Dihydroorotate-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 1997; 174:125-129.
123. Gattermann N, Dadak M, Hofhaus G, et al. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 2004; 23:1275-1279.
124. Kunz BA, Kohalmi SE, Kunkel TA, et al. Deoxyribonucleoside triphosphate levels: A critical factor in the maintenance of genetic stability. Mutat Res 1994; 318:1-64.
125. Loveland B, Wang C-R, Yonekawa H, et al. Maternally transmitted histocompatibility antigen of mice: A hydrophobic peptide of a mitochondrially encoded protein. Cell 1990; 60:971-980.
126. Renneville A, Quesnel B, Charpentier A, et al. High occurrence of JAK2 V617 F mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20:2067-2070.
127. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617 F mutation. Blood 2006; 108:2173-2181.
128. Remacha AF, Nomdedeu JF, Puget G, et al. Occurrence of the JAK2 V617 F mutation in the WHO provisional entity: Myelodysplastic/myeloproliferative disease, unclassifiable refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006; 91:719-720.
129. Boissinot M, Garand R, Hamidou M, et al. The JAK2-V617 F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ringed sideroblasts (RARS). Blood 2006; 108:1781-1782.
130. Wang SA, Hasserjian RP, Loew JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006; 20:1641-1644.
131. 9/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007; 109:1334-1335.
132. Zipperer E, Wulfert M, Germing U, et al. MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 × 109/l. Ann Hematol 2008; 87:413-415.